• Surrogate BBB Model for CNS Permeability Prediction

  2026-10-09

  Hu et al. developed a high-throughput surrogate blood–brain barrier model that combines LLC-PK1-MOCK/MDR1 cells with correction for lysosomal trapping. Across 41 compounds, the platform linked in vitro permeability with unbound brain distribution and improved interpretation of compounds whose apparent transport was distorted by intracellular sequestration.

• Recombinant Mouse M-CSF: Evidence Guide

  2026-10-09

  Recombinant Mouse M-CSF, Tag Free is a CSF1-labeled research reagent whose established biological context is CSF1R-dependent macrophage-lineage regulation. The supplied melatonin study supports a separate LPS–TLR4/TRIF–IRF3–Aanat axis and does not directly establish an M-CSF effect.

• Human SAN–Cardiac Plexus Assembloids

  2026-10-08

  A 2026 Cell Stem Cell study develops human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like tissues to model neuro-pacemaker interactions. By integrating electrophysiology, organoid-based functional analysis, and human SAN spatial transcriptomics, the authors identify a PSAP–GPR37 signaling program associated with pacemaker maturation.

• Sunitinib in RTK and Glioma Research

  2026-10-08

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor used in research on RTK signaling, tumor angiogenesis, and cancer-cell survival. This overview examines its proposed relevance to ATRX-deficient high-grade glioma, compares the strength of cellular and supplier-level evidence, and explains why findings from glioma, renal cell carcinoma, and other models should not be treated as interchangeable.

• Mitochondrial Remodeling as a New Osteogenesis Lever

  2026-10-07

  A translational perspective on how PFKM-linked metabolic signaling, ER–mitochondria communication, and mitochondrial quality control may reshape osteogenic research—and where an ER-EGFP reporter can add mechanistic context.

• IWP-2: Mechanism, Evidence, and Research Context

  2026-10-07

  IWP-2 is a Porcupine-targeting Wnt production inhibitor used to study secreted Wnt biology. This overview compares supplier-reported cancer and immune findings with a separate schizophrenia epigenetics study, emphasizing provenance, interpretation, and evidence limitations.

• CHIR-99021 and Human Sensory Neuron Models

  2026-10-06

  CHIR-99021 (CT99021) is best understood not only as a GSK-3 inhibitor, but as a cell-state variable in human iPSC-derived sensory neuron research. This article connects Wnt pathway modulation with the evidence, innovation, and limitations of a scalable HSV-1 latency model.

• IWP-2: Evidence, Mechanism, and Limits

  2026-10-06

  A source-grounded overview of IWP-2 as a Wnt production inhibitor, examining its proposed mechanism, evidence in mouse corneal epithelial research, interpretation of pathway and phenotype findings, relevance to cancer research, and key limitations.

• CHIR-99021: From GSK-3 Biology to Translation

  2026-10-05

  CHIR-99021 (CT99021) is best viewed as a mechanistic probe for testing how GSK-3 activity shapes cell identity, lineage decisions, and multicellular tissue behavior. This article connects stem cell signaling with emerging neuroimmune evidence while separating established findings from translational hypotheses.

• WNT5a–GSK3–β-Catenin Control of FAP Adipogenesis

  2026-10-05

  The 2020 Cell Death & Differentiation study identifies a WNT5a/GSK3/β-catenin axis that regulates adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors. By integrating pharmacology, mass cytometry, network modeling, and transcriptomic data, the authors connect β-catenin activity with reduced pathological fat formation and improved support for muscle satellite-cell differentiation, while leaving important questions about specificity and clinical translation open.

• Salinomycin in Cancer Research: Evidence and Limits

  2026-10-04

  Salinomycin is a polyether ionophore antibiotic investigated as a possible anticancer compound, including in hepatocellular carcinoma research. Current evidence supports mechanistic interest and preclinical hypothesis generation, but toxicity, endpoint interpretation, incomplete source provenance, and the absence of clinical evidence limit conclusions about therapeutic use.

• CHIR-99021 and Wnt Signaling: Evidence Context

  2026-10-03

  A source-grounded overview of CHIR-99021 (CT99021) as a research probe for GSK-3-linked signaling, with emphasis on Wnt/β-catenin biology, semaphorin receptor regulation, conceptual stem-cell applications, evidence strength, and important limits on interpretation.

• DFO for Fingerprints: Signal, Substrate, and Specificity

  2026-10-02

  DFO (9H-1,8-Diazafluoren-9-one) is an amino acid-reactive fluorescent reagent for visualizing latent prints on porous evidence. This article presents a decision-focused framework for substrate effects, identity control, formulation, imaging, and the important distinction between forensic DFO and deferoxamine.

• HLY78: Wnt/β-Catenin Pathway Modulator Guide

  2026-10-01

  HLY78 is a ligand-dependent Wnt/β-catenin pathway modulator for separating receptor-level signaling from constitutive pathway activation. This guide translates its Axin-LRP6 mechanism into zebrafish, stem-cell, and oral fibrosis assay workflows with practical controls and troubleshooting.

• Isoproterenol sulfate dihydrate for Pacemaker Models

  2026-10-01

  Use Isoproterenol sulfate dihydrate as a controlled acute beta-adrenergic challenge in human SAN, cardiac plexus, and atrial assembloid systems. The workflow separates rapid cAMP/PKA-linked rate responses from slower innervation-associated maturation, improving interpretation of advanced cardiovascular research assays.

8537 records 2/570 page Previous Next 12345 下5页 Last page